Maximizing Value and Equity: CMS Must Prioritize Value, Equity, and Patient Engagement in Drug Price Negotiation Program Implementation
By Jason Spangler, MD, MPH, FACPM (CEO, Innovation and Value Initiative) In March, the Centers for Medicare and Medicaid Services (CMS) released draft guidance for its implementation of the Drug Price Negotiation Program (DPNP), a key component of the Inflation Reduction Act (IRA). This release and its associated comment period sparked far-ranging debate and [...]